Propella Therapeutics, Inc., a biopharmaceutical company focused on developing innovative, best-in-class oncology drugs, announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PRL-02 (abiraterone decanoate), a potentially best-in-class therapy for metastatic prostate cancer. Propella also announced the appointment of Brendan Griffin to its leadership team as Chief Financial Officer.
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00georgehttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svggeorge2021-05-19 19:12:482022-01-04 09:10:35Press Release: Propella Therapeutics Receives FDA Clearance to Begin Phase 1 Clinical Study of Novel Prostate Cancer Treatment; Appoints Brendan Griffin, MBA as Chief Financial Officer
Propella Therapeutics, Inc. (Propella Therapeutics), a leader in the development of innovative, best-in-class prescription products, and the National Cancer Institute (NCI), announced they have entered into a Cooperative Research and Development Agreement (CRADA). Under this new partnership, Propella Therapeutics and NCI will conduct a multi-center clinical trial to evaluate abiraterone decanoate, as a new therapy for metastatic prostate cancer.
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00georgehttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svggeorge2021-02-23 16:22:522021-09-09 15:19:57Press Release: Propella Therapeutics Partners with National Cancer Institute to Develop New Treatment for Metastatic Prostate Cancer
Propella Therapeutics, Inc. presented “Abiraterone decanoate (AD): Potent and long-acting activity of a novel intramuscular (IM) abiraterone prodrug depot in a castrate monkey model” at the American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco, CA on February 11, 2021.
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00georgehttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svggeorge2021-02-22 11:33:212022-09-12 12:36:49Presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium (February 17, 2022; San Francisco, CA): Abiraterone decanoate (AD) – Potent and long-acting activity of a novel intramuscular (IM) abiraterone prodrug depot in a castrate monkey model
Propella Therapeutics, Inc. presented a webinar titled “Capsaicin: The near perfect modulator of TRPV1, the ideal osteoarthritis (OA) pain target” on February 9, 2021.
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00georgehttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svggeorge2021-02-20 00:37:592022-09-12 12:39:53Presentation (Webinar, February 9, 2021): Capsaicin – The near perfect modulator of TRPV1, the ideal osteoarthritis (OA) pain target
Propella Therapeutics, Inc. presented the results of its completed Phase 2 double-blind clinical trial (which examined the tolerability, safety and effects of CGS-200-5 (5% capsaicin topical liquid) on osteoarthritis knee pain) at the 13th Annual Pain Therapeutics Summit in Washington, DC on September 23, 2019.
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00georgehttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svggeorge2021-01-14 15:57:112021-09-09 15:20:20Capsaicin cream 0.025% as Monotherapy for Osteoarthritis: A double-blind study
Press Release: Propella Therapeutics Receives FDA Clearance to Begin Phase 1 Clinical Study of Novel Prostate Cancer Treatment; Appoints Brendan Griffin, MBA as Chief Financial Officer
Propella Therapeutics, Inc., a biopharmaceutical company focused on developing innovative, best-in-class oncology drugs, announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PRL-02 (abiraterone decanoate), a potentially best-in-class therapy for metastatic prostate cancer. Propella also announced the appointment of Brendan Griffin to its leadership team as Chief Financial Officer.
Press Release: Propella Therapeutics Partners with National Cancer Institute to Develop New Treatment for Metastatic Prostate Cancer
Propella Therapeutics, Inc. (Propella Therapeutics), a leader in the development of innovative, best-in-class prescription products, and the National Cancer Institute (NCI), announced they have entered into a Cooperative Research and Development Agreement (CRADA). Under this new partnership, Propella Therapeutics and NCI will conduct a multi-center clinical trial to evaluate abiraterone decanoate, as a new therapy for metastatic prostate cancer.
Presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium (February 17, 2022; San Francisco, CA): Abiraterone decanoate (AD) – Potent and long-acting activity of a novel intramuscular (IM) abiraterone prodrug depot in a castrate monkey model
Propella Therapeutics, Inc. presented “Abiraterone decanoate (AD): Potent and long-acting activity of a novel intramuscular (IM) abiraterone prodrug depot in a castrate monkey model” at the American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco, CA on February 11, 2021.
Presentation (Webinar, February 9, 2021): Capsaicin – The near perfect modulator of TRPV1, the ideal osteoarthritis (OA) pain target
Propella Therapeutics, Inc. presented a webinar titled “Capsaicin: The near perfect modulator of TRPV1, the ideal osteoarthritis (OA) pain target” on February 9, 2021.
Presentation at the 13th Annual Pain Therapeutics Summit (September 23, 2019; Washington, DC): A phase 2 double-blind clinical trial (VZU00025) to examine the tolerability, safety and effects of CGS-200-0 (Vehicle), CGS-200-1 (1% Capsaicin Topical Liquid) and CGS-200-5 (5% Capsaicin Topical Liquid) on osteoarthritis knee pain (OAKP)
Propella Therapeutics, Inc. presented the results of its completed Phase 2 double-blind clinical trial (which examined the tolerability, safety and effects of CGS-200-5 (5% capsaicin topical liquid) on osteoarthritis knee pain) at the 13th Annual Pain Therapeutics Summit in Washington, DC on September 23, 2019.
Capsaicin cream 0.025% as Monotherapy for Osteoarthritis: A double-blind study